研究概要
TIL(肿瘤浸润淋巴细胞)疗法最近获批用于黑色素瘤患者;然而,在TIL制备过程中T细胞亚群的动态变化仍知之甚少。
中文摘要
TIL(肿瘤浸润淋巴细胞)疗法近期已获批用于黑色素瘤患者;然而,TIL制备过程中T细胞亚群的动态变化仍知之甚少。在此,我们利用配对单细胞RNA和TCR测序,分析了体外TIL培养不同阶段的上皮性卵巢癌样本。我们还评估了所鉴定TIL亚群的扩增潜力和肿瘤反应性。单细胞转录组分析显示,CD8+ TIL在体外扩增后表现出细胞多样性降低,选择性扩增了干细胞样TCF7+耗竭T细胞前体(Tpex)和效应样组织驻留记忆(Trm)细胞。TCR克隆型分析表明,Tpex细胞通过自我更新积累,而Trm细胞主要起源于肿瘤中的TCF7+ GZMK+早期效应记忆细胞。此外,TCR追踪鉴定出CD4+滤泡辅助性T(Tfh)样细胞,尤其是TCF7+细胞,发生优先激活和重编程。所有三个TCF7+亚群在体外均表现出强大的扩增潜力和肿瘤反应性。值得注意的是,肿瘤微环境中富集TCF-1+ CD8+ Tpex和CD4+ Tfh样细胞的CCR7+ CD200+ T细胞,在体外扩增过程中表现出自我更新,并在体内和体外均表现出肿瘤反应性。这些发现突出了TIL培养过程中肿瘤反应性TCF7+ T细胞的选择性扩增,并提示CCR7和CD200可作为生成干细胞样、肿瘤反应性细胞的重要表面标志物,有望改善癌症中的TIL疗法。
展开英文摘要原文
Tumor-infiltrating lymphocyte (TIL) therapy was recently approved for melanoma patients; however, the dynamic changes in T cell subpopulations during TIL production remain poorly understood. Here, we analyzed epithelial ovarian cancer samples at various stages of ex vivo TIL culture using paired single-cell RNA and TCR sequencing. We also assessed the expansion potential and tumor reactivity of the identified TIL subpopulations. Single-cell transcriptomic analysis revealed that CD8 + TILs exhibited reduced cellular diversity following ex vivo expansion, selectively expanding stem-like TCF7 + precursors of exhausted T cells (Tpex) and effector-like tissue-resident memory (Trm) cells. TCR clonotype analysis showed that Tpex cells accumulated through self-renewal, while Trm cells primarily originated from TCF7 + GZMK + early effector memory cells in tumors. Additionally, TCR tracing identified preferential activation and reprogramming of CD4 + T follicular helper (Tfh)-like cells, especially TCF7 + ones. All three TCF7 + subpopulations showed robust expansion potential and tumor reactivity in vitro. Notably, CCR7 + CD200 + T cells, enriched for TCF-1 + CD8 + Tpex and CD4 + Tfh-like cells in the tumor microenvironment, exhibited self-renewal during in vitro expansion and demonstrated tumor reactivity both in vivo and in vitro. These findings highlight the selective expansion of tumor-reactive TCF7 + T cells during TIL culture and suggest that CCR7 and CD200 serve as important surface markers for generating stem-like, tumor-reactive cells, potentially improving TIL therapy in cancers.
论文信息
- 作者
- Liu D、Zhang T、Sun Q、Cai D、Lou Y、Wang G、Xie B、Zhu Y
- 第一作者单位
- Clinical and Translational Research Center, Department of Biobank, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 201204, China.China
- 通讯作者单位
- Shanghai Immune Therapy Institute, New Cornerstone Science Laboratory, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital, Shanghai, 200127, China. dongchen@westlake.edu.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Science China. Life sciences2025 Oct